FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156457299> ?p ?o ?g. }

• W3156457299 abstract "Background: Antivirals are infrequently prescribed in primary care for influenza-like-illness (ILI), mostly because of perceived ineffectiveness in real world primary care, and as individuals who will especially benefit have not been identified in independent trials. We aimed to determine whether adding antiviral treatment to usual primary care for patients with ILI reduces time to recovery overall and in key subgroups.Methods: We conducted an open-label, pragmatic, randomized controlled trial of adding oseltamivir to usual care in patients aged one year and older consulting with ILI in primary care. The primary endpoint was time to recovery (return to usual activities, with fever, head- and muscle-ache minor/absent), following a Bayesian piece-wise exponential model. Baseline nasopharyngeal swabs were analyzed after study completion.Findings: We ascertained the primary outcome for 3059 of the 3266 participants recruited in 15 European countries during three seasonal influenza seasons (2015-2018); 52.0% (1590/3059) had PCR-confirmed influenza infection. Time to recovery was shorter in those given oseltamivir by 1.02 days (95% Bayesian CI: 0.73-1.32). Hazard ratios of proportional benefit were similar across pre-specified subgroups; absolute benefit in time to recovery varied, with an estimated benefit of >2 days in older patients, more severe illness, comorbidity, or longer prior illness duration. The effect was independent of influenza status. Fewer antibiotics were prescribed in the oseltamivir arm (9.3% vs 13.2%, mean difference 4.0; 95% CI: 1.7-6.3), while nausea and/or vomiting was shorter in usual care patients (HR 0.92; 95% CI: 0.85-1.00).Interpretation: Primary care patients with ILI treated with oseltamivir recovered sooner than those managed by usual care alone, irrespective of influenza virus test results. Older, sicker, patients with comorbidities and longer prior illness duration showed greater absolute benefit.Trial Registration: The trial is registered with the ISRCTN Registry, number ISRCTN27908921.Funding Statement: CB reports receiving advisory board fees from Roche Molecular Systems and grant support from Roche Molecular Diagnostics; CB was supported by funding from an NIHR Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance, by the NIHR MedTech and In Vitro Diagnostics Co-Operative at Oxford NHS Foundation Trust, and by an NIHR Senior Investigator Award.TV is PI in a project that is funded by Innovative Medicines Initiative (IMI) of the European Union, in which Janssen Pharmaceutica is a partner and researcher in another IMI project in which Biocartis, Janssen, Biomerieux and Berry Consultants are partners. In addition he is co PI of a NIHR funded RCT, and PI in several studies funded by the Netherlands Organization of Health Research and Development. CL has received advisory boards fees from MSD and grant support from GILEAD, Global Bridges, Servier, Galenica-Olvos.Declaration of Interests: CB reports receiving advisory board fees from Roche Molecular Systems and grant support from Roche Molecular Diagnostics; CB was supported by funding from an NIHR Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance, by the NIHR MedTech and In Vitro Diagnostics Co-Operative at Oxford NHS Foundation Trust, and by an NIHR Senior Investigator Award. TV is PI in a project that is funded by Innovative Medicines Initiative (IMI) of the European Union, in which Janssen Pharmaceutica is a partner and researcher in another IMI project in which Biocartis, Janssen, Biomerieux and Berry Consultants are partners. In addition he is co PI of a NIHR funded RCT, and PI in several studies funded by the Netherlands Organization of Health Research and Development. CL has received advisory boards fees from MSD and grant support from GILEAD, Global Bridges, Servier, Galenica-Olvos. All other authors declare no conflict of interest.Ethics Approval Statement: All participating countries gained national research ethics committees and CTA approval as required. Ethics Ref: 15/SC/0138." @default.
• W3156457299 created "2021-04-26" @default.
• W3156457299 creator A5006611272 @default.
• W3156457299 creator A5008009042 @default.
• W3156457299 creator A5010374583 @default.
• W3156457299 creator A5012044853 @default.
• W3156457299 creator A5012711878 @default.
• W3156457299 creator A5013804382 @default.
• W3156457299 creator A5014502334 @default.
• W3156457299 creator A5018546528 @default.
• W3156457299 creator A5019541532 @default.
• W3156457299 creator A5020462726 @default.
• W3156457299 creator A5025652170 @default.
• W3156457299 creator A5029134034 @default.
• W3156457299 creator A5029374864 @default.
• W3156457299 creator A5031679158 @default.
• W3156457299 creator A5036993000 @default.
• W3156457299 creator A5038153341 @default.
• W3156457299 creator A5041746833 @default.
• W3156457299 creator A5042467120 @default.
• W3156457299 creator A5048833108 @default.
• W3156457299 creator A5052404157 @default.
• W3156457299 creator A5055217721 @default.
• W3156457299 creator A5058496095 @default.
• W3156457299 creator A5060031392 @default.
• W3156457299 creator A5060618362 @default.
• W3156457299 creator A5068349337 @default.
• W3156457299 creator A5068530075 @default.
• W3156457299 creator A5068567085 @default.
• W3156457299 creator A5075338027 @default.
• W3156457299 creator A5078058351 @default.
• W3156457299 creator A5084030934 @default.
• W3156457299 creator A5085701170 @default.
• W3156457299 creator A5086002595 @default.
• W3156457299 creator A5089113247 @default.
• W3156457299 creator A5089425019 @default.
• W3156457299 creator A5090591123 @default.
• W3156457299 date "2019-01-01" @default.
• W3156457299 modified "2023-09-23" @default.
• W3156457299 title "Oseltamivir Plus Usual Care versus Usual Primary Care for Influenza-Like-Illness: An Open-Label, Pragmatic, Randomized Controlled Trial" @default.
• W3156457299 doi "https://doi.org/10.2139/ssrn.3448017" @default.
• W3156457299 hasPublicationYear "2019" @default.
• W3156457299 type Work @default.
• W3156457299 sameAs 3156457299 @default.
• W3156457299 citedByCount "0" @default.
• W3156457299 crossrefType "journal-article" @default.
• W3156457299 hasAuthorship W3156457299A5006611272 @default.
• W3156457299 hasAuthorship W3156457299A5008009042 @default.
• W3156457299 hasAuthorship W3156457299A5010374583 @default.
• W3156457299 hasAuthorship W3156457299A5012044853 @default.
• W3156457299 hasAuthorship W3156457299A5012711878 @default.
• W3156457299 hasAuthorship W3156457299A5013804382 @default.
• W3156457299 hasAuthorship W3156457299A5014502334 @default.
• W3156457299 hasAuthorship W3156457299A5018546528 @default.
• W3156457299 hasAuthorship W3156457299A5019541532 @default.
• W3156457299 hasAuthorship W3156457299A5020462726 @default.
• W3156457299 hasAuthorship W3156457299A5025652170 @default.
• W3156457299 hasAuthorship W3156457299A5029134034 @default.
• W3156457299 hasAuthorship W3156457299A5029374864 @default.
• W3156457299 hasAuthorship W3156457299A5031679158 @default.
• W3156457299 hasAuthorship W3156457299A5036993000 @default.
• W3156457299 hasAuthorship W3156457299A5038153341 @default.
• W3156457299 hasAuthorship W3156457299A5041746833 @default.
• W3156457299 hasAuthorship W3156457299A5042467120 @default.
• W3156457299 hasAuthorship W3156457299A5048833108 @default.
• W3156457299 hasAuthorship W3156457299A5052404157 @default.
• W3156457299 hasAuthorship W3156457299A5055217721 @default.
• W3156457299 hasAuthorship W3156457299A5058496095 @default.
• W3156457299 hasAuthorship W3156457299A5060031392 @default.
• W3156457299 hasAuthorship W3156457299A5060618362 @default.
• W3156457299 hasAuthorship W3156457299A5068349337 @default.
• W3156457299 hasAuthorship W3156457299A5068530075 @default.
• W3156457299 hasAuthorship W3156457299A5068567085 @default.
• W3156457299 hasAuthorship W3156457299A5075338027 @default.
• W3156457299 hasAuthorship W3156457299A5078058351 @default.
• W3156457299 hasAuthorship W3156457299A5084030934 @default.
• W3156457299 hasAuthorship W3156457299A5085701170 @default.
• W3156457299 hasAuthorship W3156457299A5086002595 @default.
• W3156457299 hasAuthorship W3156457299A5089113247 @default.
• W3156457299 hasAuthorship W3156457299A5089425019 @default.
• W3156457299 hasAuthorship W3156457299A5090591123 @default.
• W3156457299 hasConcept C126322002 @default.
• W3156457299 hasConcept C168563851 @default.
• W3156457299 hasConcept C187212893 @default.
• W3156457299 hasConcept C203092338 @default.
• W3156457299 hasConcept C207103383 @default.
• W3156457299 hasConcept C2779134260 @default.
• W3156457299 hasConcept C2780374985 @default.
• W3156457299 hasConcept C2780580376 @default.
• W3156457299 hasConcept C3008058167 @default.
• W3156457299 hasConcept C44249647 @default.
• W3156457299 hasConcept C524204448 @default.
• W3156457299 hasConcept C71924100 @default.
• W3156457299 hasConceptScore W3156457299C126322002 @default.
• W3156457299 hasConceptScore W3156457299C168563851 @default.
• W3156457299 hasConceptScore W3156457299C187212893 @default.
• W3156457299 hasConceptScore W3156457299C203092338 @default.
• W3156457299 hasConceptScore W3156457299C207103383 @default.
• W3156457299 hasConceptScore W3156457299C2779134260 @default.
• W3156457299 hasConceptScore W3156457299C2780374985 @default.

• next